Xconomy

DECEMBER 28, 2016

Patients with spinal muscular atrophy got some good news last week when the FDA approved nusinersen (Spinraza) , making it the first marketed drug ever for the rare and potentially deadly genetic disease. The per-injection price translates into $750,000 for. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 63

Pricing News Marketing San Diego 63

Xconomy

NOVEMBER 19, 2018

Cibus, which has developed a proprietary gene-editing technology that tweaks crops’ DNA to improve yield, is planning to make its public market debut. The San Diego-based biotech set a preliminary $100 million target for its IPO in documents filed with securities regulators Friday.

San Diego 72

San Diego Research Startup Pricing 72

Xconomy

APRIL 17, 2019

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more shares into the public markets than it had initially planned. million shares at $18 apiece, raising $166.5 million before discounts, commissions, and offering expenses.

Pricing 57

Pricing Demand Marketing Develop 57

Xconomy

SEPTEMBER 19, 2016

Amid the hue and cry over the Mylan EpiPen pricing debacle , Hillary Clinton unveiled her “ Plan to Respond to Unjustified Price Hikes for Long-Available Drugs. ” Clinton’s plan calls for “dedicated oversight to protect consumers.” That dependence on price increases won’t change any time soon.

Pricing 40

Pricing Competition Blogging Journal 40

Xconomy

MAY 10, 2019

The market for drugs for rare or “orphan” diseases continues to grow. The field has gotten so competitive that multiple products are on the market for some diseases. Patients with the rare, debilitating transthyretin amyloidosis had no marketed. Soon there could be three.

Pricing 97

Pricing Sales Competition Report 97

Xconomy

SEPTEMBER 6, 2019

Being first to market with a new type of drug brings advantages. It grabs market share that followers have to steal away. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. But the first mover isn’t infallible if someone else has something better.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

FEBRUARY 4, 2019

Battery-technology business Maxwell Technologies has agreed to be acquired by Silicon Valley electric car company Tesla (NASDAQ: TSLA ) in an all-stock deal valued at about $218 million, the San Diego-based company announced Monday. apiece, a 55 percent premium over its stock price as of market close Feb.

Technology 46

Technology San Diego Pricing News 46

Xconomy

APRIL 13, 2017

Tocagen raised $85 million in its stock market debut today, and underwriters saw enough demand to increase the number of shares in the initial public offering. San Diego-based Tocagen (NASDAQ: TOCA ) priced its offering of 8.5 million shares priced between $10 to $12 each. million shares at $10 per share.

San Diego 66

San Diego Pricing Demand Marketing 66

Xconomy

SEPTEMBER 13, 2017

Last week, the first genetically modified cell therapy came to market with a price tag of $475,000. The national debate over the high cost of healthcare, with prescription drugs at the center, resonates from the chambers of Congress to every American’s pocketbook. And it’s growing fiercer by the day.

Pricing 49

Pricing Marketing San Diego Blogging 49

Xconomy

JANUARY 31, 2020

million more shares than anticipated and pricing at the high end of its planned range. The stock price closed at $21.80, up 28 percent. The company joins the public markets with four product candidates in its pipeline, all topical non-steroidal treatments being developed for seven dermatological indications.

Westlake Village 114

Westlake Village Pricing Develop Development 114

Xconomy

JULY 26, 2019

What will the legacy be of Jeff Leiden, the longtime CEO of Vertex Pharmaceuticals? Vertex surprised Wall Street this week by announcing Leiden’s seven-year run will end next spring. In some ways, his legacy is already written. He steered Vertex through a crisis when its hepatitis C business was squashed by competition.

Pricing 77

Pricing Competition San Diego Patents 77

Xconomy

JUNE 16, 2016

What does it take to build a startup in today’s market? Put a half-dozen entry-level tech entrepreneurs together anywhere outside of the Bay Area, and it won’t take long before they start listing the local market deficiencies. In San Diego, the complaints often focus on the relative scarcity of venture capital and hometown VC firms.

Venture Capital 49

Venture Capital San Diego Truecar Web 49

Xconomy

FEBRUARY 21, 2020

The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition. The FDA has historically regarded insulin as a drug.

Pricing 79

Pricing Competition Product Marketing 79

Xconomy

MAY 9, 2019

It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least one more is coming.

Pricing 110

Pricing Research Capital Marketing 110

Xconomy

MARCH 9, 2018

Scanning loyalty cards at checkout is a lost opportunity,” says Eliahu Sussman, marketing manager at Aila Technologies, a Boston-area maker of retail devices such as digital kiosks and handheld scanners. “We That could be about to change, though.

Pricing 69

Pricing Advertising Ideas Artificial Inteligence 69

Xconomy

MAY 17, 2019

During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. But such tools only work when companies play fair.

Pricing 79

Pricing Competition Tool Marketing 79

Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. If approved this week or next, it would be just the second gene therapy to come to market in the US. healthcare system must.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

AUGUST 10, 2018

First is Alnylam Pharmaceuticals, which has spent 16 years and over $2 billion to try to bring an unproven form of medicine, RNA interference (RNAi), to market. Two imminent FDA rulings on two separate drugs aren’t just noteworthy for the patients they’ll help, but the long and winding road their developers have taken to get to this point.

News 57

News Pricing Help Marketing 57

Xconomy

OCTOBER 6, 2016

Headed by the computational neuroscientist Eugene Izhikevich, the company maintained a low profile at Qualcomm’s San Diego headquarters until 2013, when Brain Corp. two years ago as vice president of marketing and product development. began life in 2009 with a lofty goal of reverse-engineering the human brain. While Brain Corp.

Product 106

Product Artificial Inteligence San Diego Training 106

Xconomy

JANUARY 12, 2018

gene therapy, a single, long-lasting treatment called voretigene neparvovec (Luxturna) for rare, inherited blindness, is now on the market. After decades of research and scientific ups and downs, the first U.S. But the commercial challenge facing its developer, Spark Therapeutics, is daunting.

Pricing 55

Pricing Research Marketing Develop 55

Xconomy

OCTOBER 27, 2016

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. The increase in dollars flowing to agtech comes despite commodity prices that are down 65 percent from their 2013 peak, the report says. They also queried 15 VC firms.

Venture Capital 40

Venture Capital Pricing Invest Report 40

Xconomy

OCTOBER 28, 2016

THIS WEEK IN DRUG PRICING…. —A coalition of investors pressed drug makers to justify price increases. The group filed shareholder resolutions with 11 companies and cited a Kaiser Family Foundation poll that cited Americans’ concerns over drug prices.

Pricing 40

Pricing Conference News Study 40

Xconomy

MAY 16, 2018

For some migraine sufferers, bright lights or loud sounds are enough to touch off an attack. For others, stress sparks the onset of pain. Bright lights, loud sounds, stress: Migraine triggers vary from one patient to another. But a common element is the abundance of a pain-inducing protein in the blood.

Pricing 77

Pricing Develop Development San Diego 77

Xconomy

AUGUST 31, 2017

Novartis said Wednesday that it would not charge for its newly approved cellular immunotherapy, tisagenlecleucel (Kymriah)—the first so-called CAR-T product to ever come to market—if it fails to help patients within a month. The no-charge promise didn’t assuage critics of the price.

Pricing 79

Pricing Help Marketing Product 79

Xconomy

JULY 18, 2019

Initial public offerings took a brief summer break the week of Independence Day, but healthcare IPO activity resumed this week as three more companies joined the US public markets. Here’s a recap of the biotech companies that priced IPOs Wednesday evening. Read more » Reprints | Share:

Organization 77

Organization Pricing Activity Marketing 77

Xconomy

SEPTEMBER 27, 2018

The window for life science IPOs is still open, and five biotechs and one medical device company chose the last week of the third quarter to make their stock market debuts. On Thursday night, Emeryville, CA-based Gritstone priced its offering of 6.6 million shares at $15 apiece.

Pricing 94

Pricing Funding Marketing San Diego 94

Xconomy

JUNE 12, 2019

Cybersecurity firm CrowdStrike delivered the kind of market debut this week that was an unfulfilled dream for the much-anticipated IPOs of Uber and Lyft earlier this year. Sunnyvale, CA-based CrowdStrike (NASDAQ: CRWD ) priced 18 million shares of common stock at $34 on Tuesday. Trading began at $63.50 Trading began at $63.50

Pricing 54

Pricing Capital Marketing Venture Capital 54

Xconomy

JULY 25, 2019

Castle Biosciences is joining the public markets through a $64 million IPO that will support cancer tests that help doctors make treatment decisions. On Wednesday evening, Castle priced its offering of 4 million shares at $16 apiece, which was the high end of its targeted price range.

Training 60

Training Pricing Activity Help 60

Xconomy

JANUARY 29, 2019

It’s clear that Billie has addressed a real gap in the women’s personal care market by bringing product innovation and fair pricing to consumers while delivering a superior. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Product 90

Product Services Invest Pricing 90

Xconomy

MARCH 9, 2018

Trump administration health officials were out on the stump this week, talking tough about drug prices and healthcare value, encouraging the private sector to take the lead but letting everyone know the federal government is willing to push. Two came to market in 2015, chalking up relatively meager sales for their owners.

Pricing 56

Pricing Class Sales Marketing 56

Xconomy

JUNE 3, 2019

Two weeks after raising $40 million to push ahead with its drug development programs, Inhibrx submitted paperwork to the SEC revealing that it aims to raise money in the public market, too. The La Jolla, CA-based company, which is developing protein drugs targeting cancer and other diseases, was founded in 2010.

Funding 79

Funding Pricing Invest Develop 79

Xconomy

MAY 22, 2020

COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies.

Company 145

Company Companies Marketing Develop 145

Xconomy

NOVEMBER 1, 2016

They’re also a controversial part of the national debate over high drug prices, and their increased use has put ophthalmologists in the crosshairs of insurers, the federal government, and the press. The market for AMD treatments has exploded the past several years.

Pricing 40

Pricing Press Services Report 40

Xconomy

MAY 2, 2019

Beyond Meat priced its IPO Wednesday evening at $25 per share, which was the high end of its revised range. million shares at that price. The food technology company’s upsized IPO has raised $241 million to finance plans to bring its plant-based “meat” to more grocery stores and restaurants across the country.

El Segundo 82

El Segundo Pricing Technology Venture Capital 82

Xconomy

MARCH 1, 2019

biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation. After years of boom times, the U.S.

Report 83

Report Pricing Sales San Diego 83

Xconomy

AUGUST 30, 2016

Petco, the privately held pet supplies company based in San Diego, said today it led a $10 million Series A financing in Los Angeles-based Petnet, a three-year-old startup developing technology-enabled pet feeders and pet food delivery service. The “SmartFeeder” ($149) is available at Amazon, BestBuy, Target, and Petco.

San Diego 52

San Diego Los Angeles Mobile Equity 52

Xconomy

JANUARY 31, 2018

Bitcoin and other cryptocurrencies have seen dramatic but volatile price surges during the past year. But this month their billions in estimated market value are eroding , amid widening suspicions against one trading platform, a half-billion-dollar heist from another exchange, and an awakened global regulatory community. The possible.

Slides 61

Slides Research Pricing Platform 61